Memo Therapeutics Partners with CSL in $328 Million Deal for Recombinant Polyclonal IgG Technology
核心洞察
Memo Therapeutics (搜索) has entered into a strategic collaboration and option agreement with CSL (搜索) to develop recombinant polyclonal IgG products using MTx's proprietary DROPZYLLA® technology platform.
The agreement includes R&D funding and potential development and sales milestones totaling up to CHF 265 million ($328 million) for the first product, plus single-digit royalties.
The collaboration aims to advance innovative IgG solutions for treating congenital or acquired immunodeficiency and autoimmune disorders.
Memo Therapeutics (搜索) AG (MTx), a late-stage biotech company based in Schlieren, Switzerland, has announced a strategic collaboration and exclusive option-to-license agreement with CSL (搜索), a global leader in developing medicines for rare and serious diseases. The partnership focuses on developing recombinant polyclonal IgG products using MTx's proprietary DROPZYLLA® technology platform.
Financial Terms and Structure
Under the Collaboration and Option Agreement, MTx will develop recombinant polyclonal IgG products while CSL (搜索) receives an option to exclusively license these products. The agreement includes R&D funding for exploratory work, technology access, and assuming CSL exercises its option, a license fee and development and sales milestones totaling up to CHF 265 million (USD 328 million) for the first product, in addition to a single-digit royalty.
Technology Platform and Applications
The collaboration leverages MTx's DROPZYLLA® technology platform, which specializes in cloning human antibody repertoires and polyclonal antibody expression. This proprietary technology functions as an antibody repertoire copying engine with high-throughput screening capabilities, retrieving and expressing antibody genes from millions of B cells at single-cell resolution while preserving cognate heavy- and light-chain pairing.
"IgG immunotherapies are used to treat a wide range of illnesses including congenital or acquired immunodeficiency and autoimmune disorders," said Erik van den Berg, CEO of MTx. "This collaboration with CSL (搜索) represents further validation of our proprietary DROPZYLLA® technology platform and our shared ambition to advance innovative IgG solutions."
Strategic Rationale
Dr. Michael Wilson, Senior Vice President, Global Research at CSL (搜索), commented on the partnership's potential: "This research collaboration combines CSL's global leadership in immunoglobulins and expertise in recombinant proteins with Memo Therapeutics (搜索)' recombinant polyclonal technology to explore new treatment options for people with rare and serious diseases."
Company Background
MTx is a late-stage biotech company focused on translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The company's lead program, potravitug, targets BKPyV (搜索) infection in kidney transplant recipients and is planned to start Phase III clinical development in 2026. BKPyV infections decrease kidney functionality and longevity, and reduce patient survival, with potravitug having the potential to become a first-in-class BKPyV disease-modifying therapy for kidney transplant patients with a market potential of up to $2 billion per annum.
In November 2025, MTx presented long-term follow-up data from its Phase II SAFE KIDNEY trial of potravitug, a highly potent human BK polyomavirus-neutralizing antibody for the treatment of BKPyV (搜索) infection in kidney transplant recipients.
The company is backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital.